MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-03-2026
Agilent Technologies Book Value 2011-2026 | A
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.39 B | 4.87 B | 4.75 B | 4.57 B | 4.84 B | 4.25 B | 4.17 B | 5.3 B | 5.29 B | 5.18 B | 4.32 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.39 B | 4.17 B | 4.81 B |
Quarterly Book Value Agilent Technologies
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.91 B | 6.74 B | 6.37 B | 6.03 B | 5.9 B | - | - | 5.78 B | 5.15 B | 5.3 B | - | 5.12 B | 4.8 B | 5.39 B | 4.95 B | 5.39 B | 4.85 B | 4.87 B | 4.87 B | 4.77 B | 5.04 B | 4.75 B | 4.75 B | 4.75 B | 4.53 B | 4.6 B | 4.6 B | 4.6 B | 4.3 B | 4.84 B | 4.84 B | 4.84 B | 4.05 B | 4.25 B | 4.25 B | 4.25 B | 4.24 B | 4.17 B | 4.17 B | 4.17 B | 5.45 B | 5.3 B | 5.3 B | 5.3 B | 5.35 B | 5.29 B | 5.29 B | 5.29 B | 4.5 B | 5.18 B | 5.18 B | 5.18 B | 3.34 B | 4.32 B | 4.32 B | 4.32 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.91 B | 3.34 B | 4.94 B |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 16.25 | 0.06 % | $ 169 M |  China |
 |
CareDx, Inc
CDNA
|
303 M | $ 20.54 | -1.25 % | $ 1.09 B |  USA |
 |
Co-Diagnostics
CODX
|
20.6 M | $ 1.51 | -1.63 % | $ 2.01 M | USA |
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 114.63 | -1.33 % | $ 9.45 B |  Irlanda |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 81.79 | 0.76 % | $ 5.52 B | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
Medpace Holdings
MEDP
|
459 M | $ 416.79 | 0.77 % | $ 12 B | USA |
 |
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
NeoGenomics
NEO
|
837 M | $ 9.18 | 2.46 % | $ 1.18 B | USA |
 |
National Research Corporation
NRC
|
14 M | $ 16.36 | -1.12 % | $ 366 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
11 B | $ 26.12 | 2.11 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
203 M | $ 5.16 | 2.38 % | $ 306 M | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 15.03 | 1.55 % | $ 454 M | USA |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M |  Israel |
 |
Senseonics Holdings
SENS
|
61 M | $ 6.32 | -1.63 % | $ 264 M | USA |
 |
Castle Biosciences
CSTL
|
456 M | $ 24.39 | 0.62 % | $ 677 M | USA |
 |
Thermo Fisher Scientific
TMO
|
110 B | $ 472.59 | 1.36 % | $ 178 B | USA |
 |
Illumina
ILMN
|
6.3 B | $ 125.08 | 3.91 % | $ 19.9 B | USA |
 |
Trinity Biotech plc
TRIB
|
-35.2 M | $ 0.61 | 1.67 % | $ 61.9 M | Irlanda |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
Twist Bioscience Corporation
TWST
|
473 M | $ 58.35 | 2.9 % | $ 3.49 B | USA |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
3.21 B | $ 163.78 | -0.04 % | $ 8.12 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
-99.3 M | $ 84.43 | 1.22 % | $ 10.6 B | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
22.4 M | $ 1.99 | 2.9 % | $ 8.8 M | USA |
 |
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
4.1 M | $ 2.16 | - | $ 4.96 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 262.98 | 2.27 % | $ 21.9 B | USA |
 |
Celcuity
CELC
|
101 M | $ 119.89 | 0.74 % | $ 5.61 B | USA |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
2.07 B | $ 9.23 | 2.39 % | $ 2 B | USA |
 |
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | USA |
 |
Myriad Genetics
MYGN
|
368 M | $ 4.71 | 0.64 % | $ 436 M | USA |
 |
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | USA |
 |
Natera
NTRA
|
706 M | $ 199.41 | 2.39 % | $ 19.6 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 193.35 | 2.13 % | $ 21.5 B | USA |